ConductScience.org, home
Efficacy and Safety Study of Netarsudil 0.02% Ophthalmic Solution Compared to Ripasudil Hydrochloride Hydrate 0.4% Ophthalmic Solution in Japanese Subjects With Primary Open Angle Glaucoma or Ocular Hypertension
API referenceFor AI assistants

Trial · NCT04620135

Participant flow24

How many started, completed or left each group, period by period.

1 to 20 of 24

Download this page as JSON
PeriodMilestoneGroupParticipantsUnits counted
Intent-to-Treat (ITT) PopulationSTARTEDNetarsudil Ophthalmic Solution 0.02% and Netarsudil Ophthalmic Solution Vehicle122
Intent-to-Treat (ITT) PopulationSTARTEDRipasudil Hydrochloride Hydrate Ophthalmic Solution 0.4%123
Intent-to-Treat (ITT) PopulationCOMPLETEDNetarsudil Ophthalmic Solution 0.02% and Netarsudil Ophthalmic Solution Vehicle118
Intent-to-Treat (ITT) PopulationCOMPLETEDRipasudil Hydrochloride Hydrate Ophthalmic Solution 0.4%120
Intent-to-Treat (ITT) PopulationNOT COMPLETEDNetarsudil Ophthalmic Solution 0.02% and Netarsudil Ophthalmic Solution Vehicle4
Intent-to-Treat (ITT) PopulationNOT COMPLETEDRipasudil Hydrochloride Hydrate Ophthalmic Solution 0.4%3
Per-Protocol (PP) PopulationSTARTEDNetarsudil Ophthalmic Solution 0.02% and Netarsudil Ophthalmic Solution Vehicle121
Per-Protocol (PP) PopulationSTARTEDRipasudil Hydrochloride Hydrate Ophthalmic Solution 0.4%122
Per-Protocol (PP) PopulationCOMPLETEDNetarsudil Ophthalmic Solution 0.02% and Netarsudil Ophthalmic Solution Vehicle117
Per-Protocol (PP) PopulationCOMPLETEDRipasudil Hydrochloride Hydrate Ophthalmic Solution 0.4%119
Per-Protocol (PP) PopulationNOT COMPLETEDNetarsudil Ophthalmic Solution 0.02% and Netarsudil Ophthalmic Solution Vehicle4
Per-Protocol (PP) PopulationNOT COMPLETEDRipasudil Hydrochloride Hydrate Ophthalmic Solution 0.4%3
Safety PopulationSTARTEDNetarsudil Ophthalmic Solution 0.02% and Netarsudil Ophthalmic Solution Vehicle122
Safety PopulationSTARTEDRipasudil Hydrochloride Hydrate Ophthalmic Solution 0.4%123
Safety PopulationCOMPLETEDNetarsudil Ophthalmic Solution 0.02% and Netarsudil Ophthalmic Solution Vehicle118
Safety PopulationCOMPLETEDRipasudil Hydrochloride Hydrate Ophthalmic Solution 0.4%120
Safety PopulationNOT COMPLETEDNetarsudil Ophthalmic Solution 0.02% and Netarsudil Ophthalmic Solution Vehicle4
Safety PopulationNOT COMPLETEDRipasudil Hydrochloride Hydrate Ophthalmic Solution 0.4%3
Study CompletionSTARTEDNetarsudil Ophthalmic Solution 0.02% and Netarsudil Ophthalmic Solution Vehicle122
Study CompletionSTARTEDRipasudil Hydrochloride Hydrate Ophthalmic Solution 0.4%123

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Next page

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT04620135/flow

API referenceFor AI assistants